Home » Authors » Jennifer Boggs

Articles by Jennifer Boggs

Genaera Raising $24.5M, Planning Evizon Phase III

Sep. 13, 2005

By Jennifer Boggs

Genaera Raising $24.5M, Planning Evizon Phase III

Sep. 13, 2005

By Jennifer Boggs

Biogen Idec Cutting Staff To Reduce Costs, Tighten Focus

Sep. 12, 2005

By Jennifer Boggs

Biogen Idec Cutting Staff To Reduce Costs, Tighten Focus

Sep. 12, 2005

By Jennifer Boggs

NeuroHealing Tackling Brain Injury With Dopamine Agonist

Sep. 9, 2005

By Jennifer Boggs

Alliance Shifts Astral Subsidiary To MultiCell, Retains One-Third

Sep. 9, 2005

By Jennifer Boggs

NeuroHealing Tackling Brain Injury With Dopamine Agonist

Sep. 9, 2005

By Jennifer Boggs

Alliance Shifts Astral Subsidiary To MultiCell, Retains One-Third

Sep. 9, 2005

By Jennifer Boggs

Series A Brings OncoMed $14M For Cancer Stem Cell Products

Sep. 8, 2005

By Jennifer Boggs

Series A Brings OncoMed $14M For Cancer Stem Cell Products

Sep. 8, 2005

By Jennifer Boggs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...